Testing for COVID-19: Increasing testing supply

What Canada is doing

Canada is mobilizing industry and providing support for research, market approval, manufacturing and access to medical supplies. We're working proactively with companies that are developing new and innovative testing technologies. We're also engaging with international regulators to share knowledge about new developments related to testing.

Increasing testing options

Health Canada reviews testing devices to assess their safety, effectiveness and quality before they're authorized for sale in Canada. For a test to be authorized by Health Canada, it must be submitted for review by the manufacturer. To date, Health Canada has authorized over 50 different COVID-19 tests. We also continue to expedite the review of COVID-19 tests, including new testing options.

Health Canada is currently prioritizing the review of:

tests that can be used at point-of-care to provide rapid diagnostic or monitoring results, including antigen tests
saliva tests (tests that use spit as the sample instead of a sample from the nose or throat)

Health Canada has received a number of antigen test applications that are under priority review. Antigen tests detect specific proteins on the surface of the virus and provide rapid results.

A small number of saliva tests have been submitted to Health Canada and are under priority review. Health Canada hasn't authorized any tests for use with saliva at this time.

Health Canada will expedite the review of any new testing technologies submitted by manufacturers, including at-home test kits (also known as "self-testing"). For at-home test kits, the manufacturer must provide data to show the test is safe and effective for Canadians to use without health care professional supervision.

In all cases, companies must provide evidence that the test is accurate and reliable before Health Canada will authorize it. Health Canada has provided guidance to manufacturers on the authorization requirements for different types of tests such as antibody tests and antigen tests.

Securing rapid tests

Public Services and Procurement Canada has purchased rapid tests on behalf of and at the direction of the Public Health Agency of Canada. This purchase ensures that the federal government can increase testing capacity with authorized, proven and effective technologies. Explore COVID-19 rapid test purchase agreements.

Rapid tests distributed in Canada

The Government of Canada has purchased over 40 million units of the following rapid tests: Abbott Panbio, Abbott ID Now, BD Veritor, and Quidel Sofia.

The tables below show the number of COVID-19 rapid tests that have been shipped in provinces and territories as of June 17, 2021 (deployment data as of June 11, 2021). The data for “tests deployed” show the quantities of rapid tests that have been distributed to their final point-of-care setting where they will be administered to patients. The data for “tests used” depict how many of those rapid tests have been administered.

There is a delay in the reporting on the deployment of rapid tests. This is due to the time when tests are:

shipped and delivered to provinces and territories
redistributed throughout each jurisdiction

The numbers listed are updated once a week.

Canada

Distribution of tests in Canada
Product name	Tests received	Tests shipped to PTs and Federal Allocation	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}	Emergency supply
Abbott ID Now	6,611,544	4,268,088	1,361,907	351,894	2,343,456
Abbott Panbio	22,895,450	21,449,463	19,932,061	4,273,322	1,275,100
BD Veritor	11,599,980	7,340,280	1,943,212	204,811	4,261,710
Quidel Sofia	850,000	77,100	0	79	772,900
Total	41,956,974	33,134,931	23,237,180	4,830,106	8,653,166
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Newfoundland and Labrador

Distribution of tests for Newfoundland and Labrador
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	85,432	86,208	3,238
Abbott Panbio	304,200	304,375	14,563
BD Veritor	0	0	0
Total	389,632	390,583	17,801
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Prince Edward Island

Distribution of tests for Prince Edward Island
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	95,568	7,298	6,354
Abbott Panbio	26,400	no information provided	no information provided
BD Veritor	0	0	0
Total	121,968	7,298	6,354
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Nova Scotia

Distribution of tests for Nova Scotia
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	106,512	319	319
Abbott Panbio	569,225	291,475	248,953
BD Veritor	160,200	4,733	4,733
Total	835,937	296,527	254,005
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

New Brunswick

Distribution of tests for New Brunswick
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	78,912	12,736	0
Abbott Panbio	320,800	35,800	8,149
BD Veritor	0	0	0
Total	399,712	48,536	8,149
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Quebec

Distribution of tests for Quebec
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	822,816	419,616	140,288
Abbott Panbio	3,063,750	1,873,489	9,450
BD Veritor	911,280	565,320	28,480
Total	4,797,846	2,858,425	178,218
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Ontario

Distribution of tests for Ontario
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	1,218,144	338,508	38,319
Abbott Panbio	7,328,588	12,208,895	3,454,125
BD Veritor	2,864,160	331,426	48,725
Quidel Sofia	73,200	0	0
Total	11,483,892	12,878,829	3,541,169
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Manitoba

Distribution of tests for Manitoba
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	176,448	13,656	no information provided
Abbott Panbio	558,400	153,575	no information provided
BD Veritor	194,400	10,380	no information provided
Total	929,248	177,611	no information provided
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Saskatchewan

Distribution of tests for Saskwatchewan
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	148,416	92,448	57,759
Abbott Panbio	1,524,800	1,051,300	97,961
BD Veritor	142,560	23,070	0
Total	1,815,776	1,166,818	155,720
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Alberta

Distribution of tests for Alberta
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	537,912	189,998	78,848
Abbott Panbio	2,686,000	1,621,872	267,289
BD Veritor	838,800	802,543	81,168
Total	4,062,712	2,614,413	427,305
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

British Columbia

Distribution of tests for British Columbia
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	626,976	65,928	15,942
Abbott Panbio	1,779,650	376,405	34,250
BD Veritor	389,880	9,900	4,807
Total	2,796,506	452,233	54,999
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Yukon

Distribution of tests for Yukon
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	15,720	no information provided	no information provided
Abbott Panbio	13,600	no information provided	no information provided
BD Veritor	0	0	0
Total	29,320	0	0
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Northwest Territories

Distribution of tests for Northwest Territories
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	21,912	4,512	444
Abbott Panbio	12,800	3,825	78
BD Veritor	0	0	0
Total	34,712	8,337	522
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Nunavut

Distribution of tests for Nunavut
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	19,560	3,168	no information provided
Abbott Panbio	22,400	6,900	no information provided
BD Veritor	0	0	no information provided
Total	41,960	10,068	no information provided
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Federal allocation

Distribution of tests for Federal Operations^{Footnote *}
Product name	Tests received	Tests deployed^{Footnote **}	Tests used (as reported)^{Footnote ***}
Abbott ID Now	288,776	127,512	10,383
Abbott Panbio	411,950	245,300	57,684
BD Veritor	11,240	0	141
Quidel Sofia	3,900	0	79
Total	715,866	372,812	68,287
Footnote * The federal operations numbers include tests distributed to federal government departments such as: Department of National Defence (DND), Correctional Services Canada (CSC), the Public Health Agency of Canada (PHAC), as well as Northern, remote and Indigenous communities. Return to footnote * referrer Footnote The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote referrer Footnote * The tests used information shows data that has been reported to Health Canada to date. Return to footnote * referrer

Direct to organizations for workplace screening^{Footnote *}
Product name	Tests available	Tests deployed^{Footnote **}	Tests used (as reported)^{Footnote ***}
Abbott ID Now	24,984	0	0
Abbott Panbio	2,826,900	1,758,850	80,820
BD Veritor	1,827,760	195,840	36,757
Quidel Sofia	0	0	0
Total	4,679,644	1,954,690	117,577
Footnote * Federal distribution numbers include tests shipped to businesses, non-profit organizations, crown corporations, and distribution partners such as pharmacies and the Canadian Red Cross. Return to footnote * referrer Footnote The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote referrer Footnote * The tests used information shows data that has been reported to Health Canada to date. Return to footnote * referrer

Supporting provincial and territorial COVID-19 testing capacity

The federal government is providing $4.28 billion to the provinces and territories. This money is to help them conduct testing, perform contact tracing and share public health data that will help fight the pandemic. The goal is to ensure they have the capacity to test up to 200,000 people each day, nationwide.

Canada is also providing funding and support to improve and modernize data management across Canada. This support is to help all levels of government coordinate their efforts to contain the virus.

The table below shows the current capacity for each province and territory compared to the capacity target agreed to under the Safe Restart Agreement.

The national capacity target of about 200,000 tests each day is based on modelling. This modelling exercise indicates this capacity is enough to meet the expected demand for testing.

Provincial and territorial COVID-19 testing capacity

Testing capacity reported as of May 31, 2021.

Please consult the Coronavirus disease 2019 (COVID-19): Epidemiology update for daily and weekly updates on the average number of people tested.

In circumstances where capacity was not reported, the previous week's capacity was indicated (see *).

Newfoundland and Labrador: Target 2,500 - 3,000

COVID-19 testing capacity for Newfoundland and Labrador (Target 2,500 - 3,000^Footnote***)
Date	Projected daily maximum testing capacity
2020-09-03	1,450
2020-09-10	1,450
2020-09-17	1,450
2020-09-24	1,450
2020-10-01	1,450
2020-10-08	1,450
2020-10-15	1,450
2020-10-22	1,450
2020-10-29	1,450
2020-11-03	1,450
2020-11-10	1,450
2020-11-17	1,450
2020-11-24	1,450
2020-12-01	1,450
2020-12-08	1,450
2020-12-15	1,450
2020-12-22	1,450
2020-12-29	1,450
2021-01-05	1,450
2021-01-12	1,450
2021-01-19	1,450
2021-01-26	1,450
2021-02-02	1,450
2021-02-09	1,700
2021-02-16	1,700^{Footnote *}
2021-02-23	1,700
2021-03-02	1,700
2021-03-09	1,700
2021-03-16	1,700
2021-03-23	2,100
2021-03-29	2,100
2021-04-06	2,100
2021-04-12	2,500
2021-04-19	2,500
2021-04-26	2,500
2021-05-03	2,700
2021-05-10	2,700
2021-05-17	2,700
2021-05-24	2,700
2021-05-31	2,700
Footnote * Target updated October 6 at the request of Newfoundland and Labrador Return to footnote* referrer

Prince Edward Island: Target 835

COVID-19 testing capacity for Prince Edward Island (Target 835)
Date	Projected daily maximum testing capacity
2020-09-03	350
2020-09-10	430
2020-09-17	350
2020-09-24	350
2020-10-01	400
2020-10-08	400
2020-10-15	400 (800^Footnote**)
2020-10-22	400 (800^Footnote**)
2020-10-29	400 (800^Footnote**)
2020-11-03	400 (800^Footnote**)
2020-11-10	400 (800^Footnote**)
2020-11-17	400 (800^Footnote**)
2020-11-24	400 (800^Footnote**)
2020-12-01	400 (800^Footnote**)
2020-12-08	400^Footnote* (800^Footnote**)
2020-12-15	400 (800^Footnote**)
2020-12-22	400
2020-12-29	400
2021-01-05	600
2021-01-12	600
2021-01-19	600
2021-01-26	600
2021-02-02	700
2021-02-09	850
2021-02-16	850
2021-02-23	850
2021-03-02	850
2021-03-09	850
2021-03-16	850
2021-03-23	850
2021-03-29	850
2021-04-06	850
2021-04-12	850
2021-04-19	850
2021-04-26	850
2021-05-03	850
2021-05-10	850
2021-05-17	850
2021-05-24	850
2021-05-31	850
Footnote Revised to include the surge testing capacity available on a temporary basis. Return to footnote referrer

Nova Scotia: Target 2,500

COVID-19 testing capacity for Nova Scotia (Target 2,500)
Date	Projected daily maximum testing capacity
2020-09-03	1,500
2020-09-10	1,500
2020-09-17	1,500
2020-09-24	1,500
2020-10-01	1,500
2020-10-08	1,500
2020-10-15	1,500
2020-10-22	1,500
2020-10-29	1,500
2020-11-03	1,500
2020-11-10	1,500
2020-11-17	1,500
2020-11-24	2,500
2020-12-01	2,500
2020-12-08	2,500
2020-12-15	2,500
2020-12-22	2,500
2020-12-29	2,500
2021-01-05	2,500
2021-01-12	2,500
2021-01-19	2,500
2021-01-26	2,500
2021-02-02	2,500
2021-02-09	2,500
2021-02-16	2,500
2021-02-23	2,500
2021-03-02	2,500
2021-03-09	2,500
2021-03-16	2,500
2021-03-23	2,500
2021-03-29	2,500
2021-04-06	2,500
2021-04-12	2,500
2021-04-19	2,500
2021-04-26	2,500
2021-05-03	10,000
2021-05-10	10,000
2021-05-17	10,000
2021-05-24	10,000
2021-05-31	10,000

New Brunswick: Target 2,500 - 3,000

COVID-19 testing capacity for New Brunswick (Target 2,500 - 3,000)
Date	Projected daily maximum testing capacity
2020-09-03	1,500
2020-09-10	1,500
2020-09-17	1,500
2020-09-24	1,500
2020-10-01	1,500
2020-10-08	1,500
2020-10-15	1,500
2020-10-22	1,500
2020-10-29	2,000
2020-11-03	2,000
2020-11-10	2,000
2020-11-17	2,000
2020-11-24	2,000^Footnote*
2020-12-01	2,000
2020-12-08	2,000^Footnote*
2020-12-15	2,500
2020-12-22	2,500
2020-12-29	2,500
2021-01-05	2,500
2021-01-12	2,000
2021-01-19	2,000
2021-01-26	2,000
2021-02-02	2,000
2021-02-09	3,000
2021-02-16	3,000
2021-02-23	3,000
2021-03-02	3,000
2021-03-09	3,000
2021-03-16	3,000
2021-03-23	3,000
2021-03-29	3,000
2021-04-06	3,000
2021-04-12	3,000
2021-04-19	3,000
2021-04-26	3,000
2021-05-03	3,000
2021-05-10	3,000
2021-05-17	3,000
2021-05-24	3,000
2021-05-31	3,000

Quebec: Target 35,000

COVID-19 testing capacity for Quebec (Target 35,000)
Date	Projected daily maximum testing capacity
2020-09-03	20,000
2020-09-10	20,000
2020-09-17	20,000
2020-09-24	20,000
2020-10-01	20,000
2020-10-08	20,000
2020-10-15	20,000
2020-10-22	20,000
2020-10-29	20,000
2020-11-03	20,000
2020-11-10	20,000
2020-11-17	20,000
2020-11-24	20,000
2020-12-01	20,000
2020-12-08	35,199
2020-12-15	37,142
2020-12-22	38,846
2020-12-29	40,196
2021-01-05	37,972
2021-01-12	39,127
2021-01-19	36,929
2021-01-26	40,084
2021-02-02	40,977
2021-02-09	42,386
2021-02-16	39,497
2021-02-23	43,987
2021-03-02	41,386
2021-03-09	42,758
2021-03-16	42,427
2021-03-23	43,382
2021-03-29	44,037
2021-04-06	46,392
2021-04-12	48,221
2021-04-19	47,959
2021-04-26	47,659
2021-05-03	47,771
2021-05-10	48,098
2021-05-17	48,471
2021-05-24	46,104
2021-05-31	46,338

Ontario: Target 78,000

COVID-19 testing capacity for Ontario (Target 78,000)
Date	Projected daily maximum testing capacity
2020-09-03	35,108
2020-09-10	39,690
2020-09-17	42,434
2020-09-24	42,816
2020-10-01	42,942
2020-10-08	50,692
2020-10-15	51,397
2020-10-22	64,340
2020-10-29	67,094
2020-11-03	71,564
2020-11-10	78,964
2020-11-17	80,856
2020-11-24	81,630
2020-12-01	81,630
2020-12-08	74,008
2020-12-15	77,333
2020-12-22	77,333
2020-12-29	77,581
2021-01-05	79,821
2021-01-12	120,608
2021-01-19	120,608
2021-01-26	120,608
2021-02-02	116,000
2021-02-09	116,000
2021-02-16	116,000
2021-02-23	116,000
2021-03-02	116,000
2021-03-09	117,800
2021-03-16	118,400
2021-03-23	118,400
2021-03-29	118,400
2021-04-06	120,200
2021-04-12	120,200
2021-04-19	120,200
2021-04-26	120,200
2021-05-03	120,200
2021-05-10	124,700
2021-05-17	124,700
2021-05-24	124,700
2021-05-31	124,700

Manitoba: Target 3,000

COVID-19 testing capacity for Manitoba (Target 3,000)
Date	Projected daily maximum testing capacity
2020-09-03	3,000
2020-09-10	3,000
2020-09-17	3,000
2020-09-24	3,000
2020-10-01	3,000
2020-10-08	3,000
2020-10-15	3,000
2020-10-22	3,000
2020-10-29	3,000
2020-11-03	3,000
2020-11-10	3,000
2020-11-17	3,000
2020-11-24	3,000^Footnote*
2020-12-01	2,841
2020-12-08	2,841^Footnote*
2020-12-15	2,841^Footnote*
2020-12-22	3,500
2020-12-29	3,500
2021-01-05	3,500
2021-01-12	3,500
2021-01-19	3,500
2021-01-26	3,500
2021-02-02	3,500
2021-02-09	3,500^Footnote*
2021-02-16	3,500
2021-02-23	3,500
2021-03-02	3,500
2021-03-09	3,500^Footnote*
2021-03-16	3,500
2021-03-23^Footnote*	3,500
2021-03-29	3,500
2021-04-06	3,500^Footnote*
2021-04-12	3,500^Footnote*
2021-04-19	3,500^Footnote*
2021-04-26	3,500^Footnote*
2021-05-03	3,500^Footnote*
2021-05-10	3,500^Footnote*
2021-05-17	3,500^Footnote*
2021-05-24	3,500^Footnote*
2021-05-31	3,500^Footnote*

Saskatchewan: Target 4,000

COVID-19 testing capacity for Saskatchewan (Target 4,000)
Date	Projected daily maximum testing capacity
2020-09-03	1,800
2020-09-10	1,800
2020-09-17	1,800
2020-09-24	1,800
2020-10-01	1,800
2020-10-08	1,800
2020-10-15	1,800
2020-10-22	1,800
2020-10-29	1,800
2020-11-03	1,800
2020-11-10	2,100
2020-11-17	2,700
2020-11-24	2,700
2020-12-01	3,330
2020-12-08	3,450
2020-12-15	3,450
2020-12-22	3,450
2020-12-29	3,450
2021-01-05	3,846
2021-01-12	3,846
2021-01-19	3,846
2021-01-26	3,846
2021-02-02	3,846
2021-02-09	3,846^Footnote*
2021-02-16	3,846^Footnote*
2021-02-23	3,846
2021-03-02	3,846
2021-03-09	3,846
2021-03-16	4,000
2021-03-23	4,500
2021-03-29	4,500
2021-04-06	4,500
2021-04-12	4,500
2021-04-19	4,500
2021-04-26	4,500
2021-05-03	4,500
2021-05-10	4,500
2021-05-17	4,500
2021-05-24	4,500
2021-05-31	4,500

Alberta: Target 22,000

COVID-19 testing capacity for Alberta (Target 22,000)
Date	Projected daily maximum testing capacity
2020-09-03	12,000
2020-09-10	12,000
2020-09-17	12,000
2020-09-24	12,000
2020-10-01	15,500
2020-10-08	22,000
2020-10-15	22,000
2020-10-22	22,000
2020-10-29	22,000
2020-11-03	22,000
2020-11-10	22,000
2020-11-17	22,000
2020-11-24	22,000
2020-12-01	22,000
2020-12-08	22,000^Footnote*
2020-12-15	22,000
2020-12-22	22,000
2020-12-29	22,000
2021-01-05	22,000
2021-01-12	22,000
2021-01-19	22,000
2021-01-26	22,000
2021-02-02	22,000
2021-02-09	22,000
2021-02-16	22,000
2021-02-23	22,000
2021-03-02	22,000
2021-03-09	22,000
2021-03-16	22,000
2021-03-23	22,000
2021-03-29	22,000
2021-04-06	22,000
2021-04-12	22,000
2021-04-19	22,000
2021-04-26	22,000
2021-05-03	22,000
2021-05-10	22,000
2021-05-17	22,000
2021-05-24	22,000
2021-05-31	22,000

British Columbia: Target 20,000

COVID-19 testing capacity for British Columbia (Target 20,000)
Date	Projected daily maximum testing capacity
2020-09-03	7,842
2020-09-10	8,581
2020-09-17	7,996
2020-09-24	9,633
2020-10-01	9,714
2020-10-08	10,506
2020-10-15	10,586
2020-10-22	12,840
2020-10-29	13,685
2020-11-03	17,033
2020-11-10	17,333
2020-11-17	18,733
2020-11-24	18,733
2020-12-01	18,733
2020-12-08	18,945
2020-12-15	18,945
2020-12-22	18,945
2020-12-29	18,945
2021-01-05	19,439
2021-01-12	19,439
2021-01-19	19,817
2021-01-26	19,817
2021-02-02	19,817
2021-02-09	19,817
2021-02-16	19,817
2021-02-23	20,617
2021-03-02	20,617
2021-03-09	20,617
2021-03-16	20,617
2021-03-23	21,332
2021-03-29	21,332
2021-04-06	19,932
2021-04-12	18,932
2021-04-19	20,132
2021-04-26	20,132
2021-05-03	20,132
2021-05-10	20,132
2021-05-17	20,132
2021-05-24	20,132
2021-05-31	20,132

Yukon: Target 160

COVID-19 testing capacity for Yukon (Target 160)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	150
2020-10-08	150
2020-10-15	150
2020-10-22	150
2020-10-29	150
2020-11-03	150
2020-11-10	150
2020-11-17	150
2020-11-24	150
2020-12-01	150^Footnote*
2020-12-08	150^Footnote*
2020-12-15	150
2020-12-22	150
2020-12-22	150
2020-12-29	150
2021-01-05	150
2021-01-12	150
2021-01-19	150
2021-01-26	150^Footnote*
2021-02-02	150^Footnote*
2021-02-09	150
2021-02-16	150^Footnote*
2021-02-23	150^Footnote*
2021-03-02	150
2021-03-09	150^Footnote*
2021-03-16	150^Footnote*
2021-03-23	150
2021-03-29	150
2021-04-06	150
2021-04-12	150
2021-04-19	150
2021-04-26	150
2021-05-03	150
2021-05-10	150
2021-05-17	150
2021-05-24	150
2021-05-31	150

Northwest Territories: Target 225

COVID-19 testing capacity for Northwest Territories (Target 225)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	48
2020-10-08	48
2020-10-15	48
2020-10-22	48
2020-10-29	75
2020-11-03	75
2020-11-10	75
2020-11-17	75
2020-11-24	75
2020-12-01	75^Footnote*
2020-12-08	75^Footnote*
2020-12-15	75^Footnote*
2020-12-22	75
2020-12-29	75
2021-01-05	75
2021-01-12	75
2021-01-19	75
2021-01-26	75*
2021-02-02	110
2021-02-09	110
2021-02-16	110
2021-02-23	110
2021-03-02	110
2021-03-09	110
2021-03-16	110
2021-03-23	110
2021-03-29	110
2021-04-06	110
2021-04-12	100
2021-04-19	110
2021-04-26	110
2021-05-03	110
2021-05-10	110
2021-05-17	110
2021-05-24	110
2021-05-31	110

Nunavut: Target n/a

COVID-19 testing capacity for Nunavut (Target n/a)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	n/a
2020-10-08	n/a
2020-10-15	80
2020-10-22	80
2020-10-29	80
2020-11-03	100
2020-11-10	200
2020-11-17	200
2020-11-24	200
2020-12-01	200
2020-12-08	200
2020-12-15	250
2020-12-22	250
2020-12-29	250
2021-01-05	250
2021-01-12	250
2021-01-19	300
2021-01-26	300
2021-02-02	300
2021-02-09	300
2021-02-16	300
2021-02-23	300
2021-03-02	300
2021-03-09	300
2021-03-16	300
2021-03-23	300
2021-03-29	300
2021-04-06	300
2021-04-12	300
2021-04-19	300
2021-04-26	300
2021-05-03	300
2021-05-10	300
2021-05-17	300
2021-05-24	300
2021-05-31	300

Canada: Target 170,720 - 171,220

COVID-19 testing capacity for Canada (Target 170,720 - 171,220)
Date	Projected daily maximum testing capacity
2020-09-03	84,550
2020-09-10	89,951
2020-09-17	92,030
2020-09-24	94,049
2020-10-01	82,504
2020-10-08	113,046
2020-10-15	113,911
2020-10-22	128,838
2020-10-29	132,234
2020-11-03	141,072
2020-11-10	149,172
2020-11-17	153,064
2020-11-24	154,838
2020-12-01	155,309
2020-12-08	163,218
2020-12-15	169,036
2020-12-22	171,399
2020-12-29	172,997
2021-01-05	174,103
2021-01-12	215,545
2021-01-19	213,775
2021-01-26	216,930
2021-02-02	213,350
2021-02-09	216,159
2021-02-16	213,270
2021-02-23	218,560
2021-03-02	215,959
2021-03-09	219,131
2021-03-16	219,599
2021-03-23	222,124
2021-03-29	222,779
2021-04-06	225,534
2021-04-12	226,763
2021-04-19	227,701
2021-04-26	227,401
2021-05-03	235,213
2021-05-10	240,040
2021-05-17	240,413
2021-05-24	238,046
2021-05-31	238,280

Language selection

Search